Lanzhou Foci Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2020
April 24, 2020 at 01:23 pm IST
Share
LanZhou Foci Pharmaceutical Co.,Ltd. announced earnings results for the first quarter ended March 31, 2020. For the first quarter, the company announced sales was CNY 137.964 million compared to CNY 156.036 million a year ago. Operating income was CNY 15.788 million compared to CNY 15.275 million a year ago. Net income was CNY 13.304 million compared to CNY 12.977 million a year ago. Basic earnings per share from continuing operations was CNY 0.0261 compared to CNY 0.0254 a year ago.
LanZhou Foci Pharmaceutical Co.,Ltd is a China-based company principally engaged in the research, development, manufacture and sale of Chinese patent drugs and large health products. The Companyâs main products are categorized into pills, tablets, granules, syrups, capsules, glue and others, including Liuwei Dihuang pills, Xiaoyao Pill, Xiangsha Yangwei pills, ginseng Gubeng Huanhao pills and other Chinese patent drugs, as well as large health products, such as Ejiao and Ejiao loafs. The Company distributes its products under the brand names Foci, Baolu and Mianshan. The Company is also involved in the cultivation, processing and marketing of Chinese herbal medicine. The Company distributes its products in domestic market and to overseas markets.
LANZHOU FOCI PHARMACEUTICAL CO.,LTD. 
